Results 211 to 220 of about 1,213,487 (359)

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer [PDF]

, 2011
Chee Khoon Lee, R. J. Simes, Chris Brown, Sarah J. Lord, Uwe Wagner, Marie Plante, Ignace Vergote, Carmela Pisano, Gabriella Parma, Alexander Burges, Hugues Bourgeois, Thomas Högberg, J. Bentley, Lukas Angleitner-Boubenizek, Annamaria Ferrero, Barbara Richter, Hal W. Hirte, Val Gebski, Jacobus Pfisterer, Éric Pujade-Lauraine, Michael Friedlander   +20 more
openalex   +1 more source

The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity

Molecular Oncology, EarlyView.
Natural killer (NK) cells play a central role in anti‐melanoma immunity. However, melanoma cells adapt during co‐culture by upregulating CIITA and MHC II in response to interferon gamma (IFNγ), thereby evading NK‐cell lysis. Blocking IFNγ signaling or treatment with dimethyl fumarate/simvastatin counteracts this immune escape and maintains NK‐cell ...
Lena C. M. Krause, Rixa‐Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski   +6 more
wiley   +1 more source

Predictive Value of the KELIM Index for Progression-Free Survival in Ovarian Cancer Under Current Treatment Modalities. [PDF]

Int J Womens Health
Lv J, Xu Y, Zeng C, Huang F, Tao S.
europepmc   +1 more source

Intra-Arterial Delivery of Bevacizumab after Blood-Brain Barrier Disruption for the Treatment of Recurrent Glioblastoma: Progression-Free Survival and Overall Survival [PDF]

, 2011
Jan‐Karl Burkhardt, Howard A. Riina, Benjamin J. Shin, Paul J. Christos, Kartik Kesavabhotla, Christoph P. Hofstetter, Apostolos John Tsiouris, John A. Boockvar   +7 more
openalex   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Heterogeneity of progression-free survival surrogacy by sex in randomized trials testing immunotherapy in non-small cell lung cancer. [PDF]

JNCI Cancer Spectr
Pagan E, Sala I, Pala L, Natali F, Merlo F, Oriecuia C, Specchia C, De Pas T, Catania C, Cocorocchio E, Laszlo D, Ceresoli G, Locatelli M, Cascetta P, Facella F, Tinterri B, Pino M, Canzian J, Giaccone G, Bagnardi V, Conforti F.   +20 more
europepmc   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma [PDF]

, 2011
Sébastien J. Hotte, Georg A. Bjarnason, D.Y.C. Heng, M.A.S. Jewett, Anil Kapoor, Christian Kollmannsberger, Jean A. Maroun, Linda A. Mayhew, Scott North, M. Neil Reaume, Joseph D. Ruether, Denis Soulières, Peter Venner, Eric Winquist, Lori Wood, Jin-Young Yong, Fred Saad   +16 more
openalex   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Development of a prognostic multiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first line immunotherapy. [PDF]

Sci Rep
Singh A, Horng H, Roshkovan L, Hershman M, Cohen EA, Aggarwal C, Carpenter EL, Katz SI, Kontos D.   +8 more
europepmc   +1 more source